$8.5 billion is the estimated annual size of the U.S. anti-VEGF retina market that Outlook Therapeutics, Inc. (Nasdaq: OTLK) can now address commercially. The FDA approved LYTENAVA (bevacizumab-vikg) on July 24, 2026, for neovascular age-related macular degeneration, making it the first FDA-approved ophthalmic formulation of bevacizumab in the United States.
Exclusivity and market position
Outlook Therapeutics anticipates 12 years of Reference Product Exclusivity for LYTENAVA under the Biologics Price Competition and Innovation Act. Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, per Citeline (2023), Global Data (2023), and Market Scope (2022). OTLK's commercial thesis is conversion, not creation: physicians have administered repackaged intravenous bevacizumab for intravitreal use for more than two decades without an FDA-approved ophthalmic version. That is the volume the company is positioning to capture.
U.S. launch timeline
LYTENAVA is expected to reach eligible U.S. patients before year-end 2026. CEO Bob Jahr described commercial launch as the company's immediate mission, with reimbursement expansion and a specialized retina sales organization as the first-order priorities. Iselin, N.J.-based Outlook Therapeutics also plans patient assistance programs to support physician adoption across the country.
Existing regulatory footprint
LYTENAVA already holds approvals in two other major markets. The European Commission granted a centralized Marketing Authorization in the EU; the Medicines and Healthcare products Regulatory Agency approved it in the United Kingdom. Both cover wet AMD. Several EU member states still require individual pricing and reimbursement decisions before commercial sales can begin in those jurisdictions.
Firas M. Rahhal, MD, Chairman of Ophthalmology at Good Samaritan Hospital in Los Angeles, said the retina community has waited a long time for exactly this approval. The first hard checkpoint for OTLK is U.S. commercial availability before December 31, 2026.